Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
Add more filters










Publication year range
1.
Article in English | MEDLINE | ID: mdl-22884780

ABSTRACT

Achieving an appropriate DHA status in the neonatal brain is an important goal of neonatal nutrition. We evaluated how alpha-linolenic acid (ALA), provided for six weeks after weaning by different dietary fat matrix, improved brain DHA content of young male rats born from deficient-dams. The level of ALA achieved was based on the fat composition of usual infant vegetable formula. A palm oil-blend diet thus providing 1.5%ALA was compared to dairy fat-blend-based diets that provided either 1.5%ALA or 2.3%ALA, or a rapeseed oil diet providing 8.3%ALA (n-6/n-3 ratio were, respectively 10,10,5,2.5). The 1.5%ALA-dairy-fat-blend was superior to 1.5%ALA-palm-oil-blend to restore values of brain DHA, while the 2.3%ALA-dairy-fat-blend exhibited a further increase and reached the values obtained with pure rapeseed diet (8.3%ALA). Dairy-fat-blends enriched with ALA appear to be an interesting strategy for achieving optimal DHA levels in the brain of post-weaning rats. Providing dairy fat as well as a reduction of the LA/ALA ratio should be reconsidered to design infant formula.


Subject(s)
Brain/metabolism , Dairy Products , Dietary Fats/metabolism , Docosahexaenoic Acids/metabolism , Neurogenesis , Plant Oils/metabolism , alpha-Linolenic Acid/administration & dosage , Animals , Food, Fortified/analysis , Glycolipids/metabolism , Glycoproteins/metabolism , Humans , Infant , Infant Formula/chemistry , Infant Formula/metabolism , Lipid Droplets , Male , Neurons/metabolism , Nutritional Status , Rats , Rats, Wistar , Up-Regulation , Weaning , alpha-Linolenic Acid/deficiency , alpha-Linolenic Acid/metabolism , alpha-Linolenic Acid/therapeutic use
2.
Pharmacol Res ; 61(3): 226-33, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20036742

ABSTRACT

Populations of Western countries are severely deficient in omega-3 intake, both in the form of alpha-linolenic acid (ALA) and the Long Chain derivatives (LC-n-3), Eicosa-Pentaenoic-Acid and Docosa-Hexaenoic-Acid. Omega-3 insufficiency is a risk factor for cardiovascular and cerebral diseases such as coronary heart disease and stroke. Stroke is a major cause of mortality and morbidity, and induces a significant socioeconomic cost and a marked increase in patient/family burden. To date, preventive treatments and neuroprotective drugs identified in preclinical studies failed in clinical trials, in part because of an inability to tolerate drugs at neuroprotective concentrations. Therefore testing alternative protective strategies, such as functional foods/nutraceuticals, are of considerable interest. We have previously demonstrated that a single injection of ALA reduced ischemic damage by limiting glutamate-mediated neuronal death, whereas repeated injections displayed additive protective benefits as a result of increased neurogenesis, synaptogenesis and neurotrophin expression. Because intravenous injections are not a suitable long-term strategy in humans, the present study investigated the effect of ALA supplementation by an experimental diet containing rapeseed oil (RSO, a rich source of ALA) as the only source of lipids for stroke prevention. We tested several experimental diets which included 5, 10, and 20% RSO-enriched diet and feeding paradigms (fresh diet was provided once or twice a week for 4 or 6 weeks). Our results showed that ALA supplemented diets are more sensitive to lipid peroxidation than a regular chow diet. Because the diet affected feeding behavior and animal growth, we defined concrete guidelines to investigate the effect of omega-3 supplementation on neuropathology. Among the different sets of experiments, animals fed with 10% and 20% RSO-enriched diet displayed a reduced mortality rate, infarct size and increased probability of spontaneous reperfusion in the post-ischemic period. In addition, a drastic reduction of lipid peroxidation levels was observed in the ischemic brain of RSO-fed animals. Overall, our findings provide new insights into the potential of employing rapeseed oil as a functional food/nutraceutical aiding in stroke prevention and protection.


Subject(s)
Dietary Fats, Unsaturated/administration & dosage , Dietary Supplements , Plant Oils/administration & dosage , Stroke/prevention & control , alpha-Linolenic Acid/administration & dosage , Animals , Fatty Acids, Monounsaturated , Lipid Peroxidation/drug effects , Lipid Peroxidation/physiology , Male , Mice , Mice, Inbred C57BL , Rapeseed Oil , Stroke/metabolism , Stroke/pathology
3.
Nutr Metab Cardiovasc Dis ; 13(1): 28-36, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12772435

ABSTRACT

BACKGROUND AND AIM: Plasma cholesterol efflux capacity is stimulated during postprandial (PP) hypertriglycerdemia. Plasma cholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP) are the key proteins in lipoprotein metabolism and remodelling, but their role during the PP cholesterol efflux process remains indeterminate. The aim of this study was to determine the effect of a fatty meal intake on plasma CETP and PLTP activities, and the capacity of plasma to promote cholesterol efflux, as well as to evaluate the relationship between these three key mechanisms of the reverse cholesterol transport process. METHODS AND RESULTS: CETP and PLTP activities and the cholesterol efflux capacity of plasma were measured over eight hours following a fatty meal (1000 kcal, 62% fat) in 13 normolipidemic men. CETP activity and the cholesterol efflux capacity of plasma from Fu5AH cells increased after the meal, reaching a maximum after eight hours (respectively 32%, p = 0.06, and 6.5%, p = 0.045), whereas PLTP activity remained unchanged. CETP and PLTP activities did not correlate with plasma cholesterol efflux capacity in the fasting or PP state. Plasma CETP activity in the fasting state positively correlated with the plasma non-esterified fatty acid (NEFA) levels, but no correlation was found with any lipid or apolipoprotein postprandially. The cholesterol efflux capacity of plasma correlated positively with high-density lipoprotein (HDL) components, the best correlation being with the HDL phospholipid fraction in both the fasting and PP states. CONCLUSIONS: These findings suggest that plasma CETP and PLTP activities in healthy normolipidemic subjects are differently regulated in the PP state, and are not correlated with the increased cholesterol efflux capacity of PP plasma. HDL-phospholipid remains the key factor in the regulation of the capacity of plasma to promote Fu5AH cell cholesterol efflux.


Subject(s)
Carrier Proteins/blood , Cholesterol/blood , Food , Glycoproteins , Lipids/blood , Membrane Proteins/blood , Phospholipid Transfer Proteins , Adult , Aged , Cholesterol Ester Transfer Proteins , Dietary Fats/administration & dosage , Fasting , Fatty Acids, Nonesterified/blood , Humans , Kinetics , Lipoproteins, HDL/blood , Male , Middle Aged
4.
NMR Biomed ; 11(6): 273-80, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9802469

ABSTRACT

Quantitative analysis of lipoprotein major fractions, LDL, VLDL and HDL, is of great interest for medical purposes, for instance in liver or heart diseases, diet management or cancer. The presently available biochemical methods require time consuming ultracentrifugation. A potentially automated method is proposed, using time domain quantification by Wavelet Transform (WT-NMR) method. The aim of the present study was to evaluate, on a preliminary series of nine human plasmas, the potential interest of WT-NMR in the quantification of both NMR-visible lipids and total lipoprotein fractions. The correlation coefficients between low and intermediate density (LDL+IDL), very low density (VLDL) and high density (HDL) lipoprotein visible lipid quantifications, obtained on nine human plasmas with WT-NMR and standard biochemical methods, were 0.79, 0.84 and 0.92, respectively. For the total lipoprotein assay, i.e. including an estimation of non NMR-visible protein and free cholesterol, the correlation between WT-NMR and the biochemistry were 0.87 for LDL+IDL, 0.81 for VLDL and 0.88 for HDL.


Subject(s)
Lipoproteins/blood , Magnetic Resonance Spectroscopy/methods , Methane/analogs & derivatives , Blood Proteins/analysis , Cholesterol/blood , Humans , Hydrocarbons , Lipoproteins, HDL/blood , Lipoproteins, IDL , Lipoproteins, LDL/blood , Lipoproteins, VLDL/blood , Male
5.
Biochemistry ; 34(33): 10421-31, 1995 Aug 22.
Article in English | MEDLINE | ID: mdl-7654696

ABSTRACT

In cultured human and rat cells, the lipolysis-stimulated receptor (LSR), when activated by free fatty acids (FFA), mediates the binding of apoprotein B- and apoprotein E-containing lipoproteins and their subsequent internalization and degradation. To better understand the physiological role of LSR, we developed a biochemical assay that optimizes both the activation and binding steps and, thus, allows the estimation of the number of LSR binding sites expressed in the livers of living animals. With this technique, a strong inverse correlation was found in rats between the apparent number of LSR binding sites in liver and the postprandial plasma triglyceride concentration (r = -0.828, p < 0.001, n = 12). No correlation existed between the number of LSR and plasma triglycerides measured in the same animals after 24 h of fasting. The same membrane binding assay was used to elucidate the mechanism by which FFA induce lipoprotein binding to LSR. The LSR activation step was mediated by direct interaction of FFA with LSR candidate proteins of apparent molecular masses of 115 and 90 kDa and occurred independently of the membrane lipid environment. The FFA-induced conformational shift that revealed the lipoprotein binding site remained fully reversible upon removal of the FFA. However, occupancy of the site by the apoprotein ligand stabilized the active form of LSR. Comparison of the effect of different FFA alone or in combination indicated that the same binding site is revealed by different FFA and that the length and saturation of the FFA monomeric carbon chain are critical in determining the potency of the FFA activating effect. We propose that the LSR pathway represents a limiting step for the cellular uptake of intestinally derived triglyceride-rich lipoproteins and speculate that FFA liberated by lipolysis initiate this process by altering the conformation of LSR to reveal the lipoprotein binding site.


Subject(s)
Receptors, LDL/physiology , Receptors, Lipoprotein/physiology , Animals , Binding Sites , Binding, Competitive , Cell Membrane/metabolism , Cells, Cultured , Fatty Acids, Nonesterified/pharmacology , Humans , Kinetics , Lactoferrin/pharmacology , Lipoproteins, LDL/metabolism , Liver/metabolism , Male , Oleic Acid , Oleic Acids/pharmacology , Phospholipids/pharmacology , Proteoglycans/pharmacology , Rats , Rats, Sprague-Dawley , Triglycerides/blood , Trypsin/pharmacology
6.
Diabete Metab ; 21(2): 121-6, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7621972

ABSTRACT

It has been widely accepted that the remnants of the intestinally-derived lipoprotein chylomicrons, i.e., chylomicron remnants (CMR), are cleared from the circulation by a receptor genetically distinct from the well-known LDL-receptor. This second receptor was initially considered as a receptor specific for apo E, in contrast to the LDL-receptor, which binds both apo B and apoE. This article critically examines the current dogma of the putative CMR receptor, as well as both supporting and conflicting evidence for the recently-proposed identity of this receptor with the LDL-receptor related protein (LRP). Next, we introduce the lipolysis-stimulated receptor, LSR, which bears all the biochemical characteristics of the CMR receptor. In addition, the apparent number of LSR expressed in the liver is inversely correlated with nonfasting levels of plasma triglycerides. A change in LSR expression and parallel inverse change in plasma triglycerides is observed in rats treated with hyperlipidemic (retinoic acid) or hypolipidemic (fish oil in MaxEPA) agents, indicating that LSR represents a definite target for pharmacological management of hyperlipidemia. In support of this notion is the observation that MaxEPA, which causes an increase in LSR expression, also reduces both plasma triglyceride and cholesterol levels in the thus far intractable homozygous Watanabe heritable hyperlipidemic rabbit.


Subject(s)
Chylomicrons , Receptors, LDL/analysis , Receptors, Lipoprotein/analysis , Animals , Humans , Low Density Lipoprotein Receptor-Related Protein-1 , Receptors, Immunologic/analysis
7.
C R Seances Soc Biol Fil ; 189(5): 899-904, 1995.
Article in French | MEDLINE | ID: mdl-8673635

ABSTRACT

This article critically examines the concept of the putative chylomicron remnant receptor (CMR). The molecular nature of this second lipoprotein receptor remains disputed. Indeed, two proteins, the low density lipoprotein receptor-related protein (LRP) and the lipolysis stimulated receptor (LSR) have been proposed as candidates for this function. The LRP bears significant structural homology with the LDL receptor and mediates the internalisation of beta-VLDL enriched with apo E. In addition, LRP binds several ligands not related to the lipoprotein system. Thus, LRP's contribution to the clearance of CMR has been questioned. The precise biochemical structure of LSR remains unclear. However, a series of observations support the hypothesis that LSR is the CMR receptor. LSR, which is activated by free fatty acis (FFA), the products of lipolysis, is present in primary cultures of rat hepatocytes. It displays the highest affinity for triglyceride-rich lipoproteins and is inhibited by lactoferrin. The existence of a strong inverse correlation in rats between the apparent number of hepatic LSR and the plasma triglyceride concentration measured in the post-prandial state, indicate that LSR represents a rate-limiting step for the removal of triglyceride-rich lipoproteins. Moreover, the ability of MAXEPA to enhance the expression of LSR in parallel with its well documented hypotriglyceridemic effect indicates that, contrary to popular belief, the putative CMR receptor represents a target for pharmacological management of hyperlipidemia.


Subject(s)
Chylomicrons/metabolism , Intestinal Mucosa/metabolism , Liver/metabolism , Humans , Low Density Lipoprotein Receptor-Related Protein-1 , Metabolic Clearance Rate , Receptors, Immunologic/metabolism , Receptors, LDL/metabolism
8.
Atherosclerosis ; 100(2): 183-8, 1993 May.
Article in English | MEDLINE | ID: mdl-8357350

ABSTRACT

Several reports have shown that lipoprotein(a) is associated with ischemic diseases. Two characteristics might explain this association. Firstly, Lp(a) is an LDL-like lipoprotein which may be implicated in the atherosclerotic process and secondly, Lp(a) possesses an additional apolipoprotein(a) whose structure is close to that of plasminogen and might confer to the molecule prothrombotic properties. It seemed of interest to see whether Lp(a) was a risk factor in oral contraceptive users with thrombotic complications, a group of young women with presumably little or no atherosclerosis. Three groups of women were compared: 25 of them served as controls and did not use oral contraceptives (OC) (group 1); 25 women were healthy current users of OC (group 2); 35 women suffered thrombotic complications in the course of OC (group 3). Mean levels of Lp(a), estimated by RID, were not found to be significantly different in the 3 groups: 19 +/- 18, 20 +/- 23 and 16 +/- 22 mg/dl, respectively. Levels above 30 mg/dl were similarly distributed. Among the other risk factors studied, antiestrogen antibodies were absent in group 1, present in 24% of group 2 and 71.4% of group 3 (P < 0.01). Serum cholesterol levels were similar in the 3 groups: 209 +/- 33, 220 +/- 41, 213 +/- 45 mg/dl respectively. Mean serum triglyceride levels were higher in group 2 than in group 1 (61 +/- 18 and 83 +/- 32, P < 0.01), and higher in group 3 than in group 2 (116 +/- 66 and 83 +/- 32, P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antibodies/analysis , Contraceptives, Oral/adverse effects , Estrogens/immunology , Lipoprotein(a)/blood , Thrombosis/blood , Thrombosis/immunology , Adult , Female , Humans , Lipids/blood , Middle Aged , Risk Factors , Thrombosis/chemically induced
10.
Atherosclerosis ; 75(2-3): 145-55, 1989 Feb.
Article in English | MEDLINE | ID: mdl-2712860

ABSTRACT

Rabbits were fed cholesterol for 14 weeks to study the effect of probucol on atheroma formation. Three groups of animals were investigated: group CHOL was fed 1% cholesterol and served as control for group P + CHOL. fed 1% cholesterol and 1% probucol from the onset till the end of the experiment: group CHOL + P received 1% cholesterol throughout the experiment and 1% probucol during the last 4 weeks only. Plasma cholesterol concentrations were monitored at frequent intervals and were modulated by dietary perturbations so that the areas under the curve expressing plasma cholesterol changes with time, were similar in probucol and non-treated rabbits. The efficacy of long-term probucol treatment was evidenced by a significant reduction in plasma apolipoprotein A-I throughout the experiment and lower plasma TBARs during the first 6 weeks, when the hypocholesterolemic effect of probucol was also seen. Two weeks prior to the termination of the experiment, the rabbits were injected with rabbit plasma labeled with [3H]cholesteryl linoleyl ether [( 3H]CLE). Aortic atheromatosis was quantified by determination of total and cholesteryl ester (CE). The aortic cholesterol content was related to the arch, thoracic and abdominal segments, to the surface area of each segment or its dry defatted weight. Total and esterified cholesterol were highest in the aortic arch in all 3 groups when related to any of the above mentioned parameters. No statistically significant difference in aortic total cholesterol and CE content was seen among the three groups studied. The [3H]CLE recovered in the aortic segment correlated with the CE content and the [3H]CLE (dpm)/mg CE in all segments was similar. No statistically significant difference in the [3H]CLE recovered in the aortic segments among the 3 groups was seen. We conclude that in cholesterol-fed rabbits, in which the plasma cholesterol levels were maintained at comparable levels, probucol treatment did not affect plasma CE influx into the aorta and did not attenuate development of aortic atherosclerosis.


Subject(s)
Arteriosclerosis/blood , Cholesterol/blood , Phenols/pharmacology , Probucol/pharmacology , Animals , Aorta/analysis , Aorta/drug effects , Apolipoproteins/blood , Cholesterol/analysis , Cholesterol, Dietary/administration & dosage , Male , Rabbits , Triglycerides/blood
11.
Ann Med Interne (Paris) ; 139 Suppl 1: 80-2, 1988.
Article in French | MEDLINE | ID: mdl-2470282

ABSTRACT

Three patients with heterozygote type IIa hyperlipoproteinemia were treated by specific LDL apheresis with a dextran sulfate-cellulose column every two weeks. Each apheresis resulted in a fall in total cholesterolemia of about 50 p. 100 with a parallel fall in apoprotein B. The average drop of 15 p. 100 in HDL-cholesterol appeared to be due to the hemodilution induced at the end of apheresis. After two months, cholesterol and apoprotein B concentrations before removal were 15 p. 100 lower than baseline values. Treatment was well tolerated. These findings appear encouraging for the treatment of heterozygote forms of familial hyperlipoproteinemia resistant to chemotherapy.


Subject(s)
Blood Component Removal , Hyperlipoproteinemia Type II/therapy , Immunosorbent Techniques/instrumentation , Lipids/blood , Lipoproteins, LDL/blood , Lipoproteins/blood , Adult , Apolipoproteins B/blood , Blood Component Removal/instrumentation , Blood Component Removal/methods , Cellulose , Cholesterol/blood , Dextran Sulfate , Dextrans , Female , Humans , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/genetics , Male , Middle Aged
12.
Lipids ; 22(4): 241-9, 1987 Apr.
Article in English | MEDLINE | ID: mdl-3600201

ABSTRACT

Fibroblasts in culture and leukocytes have been widely used to study fatty acid and lipoprotein cellular metabolism. The present investigations were designed to study the role of nutritional and environmental factors on lipid metabolism in these two types of cells. Leukocytes freshly isolated from human blood and fibroblasts cultured in media enriched in human serum (HS) have relatively similar fatty acid distributions. However, more important differences are observed in fibroblasts cultured in media enriched with HS or with fetal bovine serum (FBS). It is obvious that the quantity and quality of fatty acids are very different in FBS and HS, but intracellular regulation ensures relative homogeneity of saturated (SFA) and monounsaturated fatty acids (MUFA) in the cells, particularly in phospholipids. The first modifications induced by different media (FBS or HS) are detected on cellular growth; the differences seem to be due more to the fatty acid (FA) quantitative supply than to the FA quality of each culture medium. The major modifications in FA composition induced by different culture media concern the polyunsaturated fatty acids (PUFA) of phospholipids, especially the n-6 family. The intracellular linoleic acid level depends on the level in the medium, but intracellular n-6 metabolite levels depend both on the level in the medium and on the growth state of the cells. The n-3 family seems to be less affected by the quality of the medium in our experiment, and the cells maintain a stable docosahexaenoic acid (22:6n-3) level. A higher content of the n-3 family in the medium induces a higher level of eicosa- or docosapentaenoic acid, rather than docosahexaenoic acid itself.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Fatty Acids, Unsaturated/metabolism , Fatty Acids/metabolism , Leukocytes/cytology , Skin/cytology , Adult , Cell Division , Cells, Cultured , Culture Media , Female , Fibroblasts/cytology , Humans , Male
13.
Atherosclerosis ; 44(3): 343-53, 1982 Sep.
Article in English | MEDLINE | ID: mdl-7150397

ABSTRACT

Oral contraceptives (OC) have been shown to induce in some women antiethinylestradiol antibodies which may be detected as circulating immune complexes by precipitation in ammonium sulphate at 25% saturation (CIC.AS). A reevaluation of the presence of CIC.AS in 644 women either receiving sex steroid hormones or not was made, and the respective role of estrogens and progestogens investigated, together with the influence of the dose. The study confirmed that CIC.AS levels were significantly different in controls (442 +/- 246 micrograms/ml serum), healthy gonadal hormone users (754 +/- 700 micrograms) and users with thrombosis (1331 +/- 1099 micrograms/ml). These results indicated that: 1. CIC.AS could be induced by synthetic estrogens as well as progestogens, but not by non-synthetic hormones; 2. the induction of CIC.AS seemed poorly dose-related, and 3. was not correlated with the duration of use; 4. in reactive women, high CIC.AS levels occurred as soon as 3 weeks after the beginning of synthetic gonadal hormones use, persisted throughout treatment and decreased slowly when discontinued; 5. in women with thrombosis CIC.AS were more frequently detected (64.7%) than in healthy users (32.2%) P less than 0.001. The importance of the immunologic changes as a risk factor in thrombosis in OC users was evaluated in comparison with other predisposing factors and tobacco smoking.


PIP: Oral contraceptives (OCs) have been shown to induce antiethinyl estradiol antibodies in some women which may be detected as circulating immune complexes by precipitation in ammonium sulphate at 25% saturation (CIC.AS). A reevaluation of the presence of CIC.AS in 644 women either receiving sex steroid hormones or not was made, and the respective role of estrogens and progestogens investigated, together with the influence of the dose. The study confirmed that CIC.AS levels were significantly different in controls (442 +or- 246 mcg/ml serum), healthy gonadal hormone users (754 +or- 700 mcg) and users with thrombosis (1331 +or- 1099 mcg/ml). These results indicated that: 1) CIC.AS could be induced by synthetic estrogens as well as progestogens but not by nonsynthetic hormones; 2) the induction of CIC.AS seemed poorly dose-related; and 3) the induction was not correlated with the duration of use; 4) high CIC.AS levels occurred as soon as 3 weeks after the beginning of synthetic gonadal hormone use in reactive women and persisted throughout treatment and decreased slowly when discontinued; and 5) CIC.AS was detected more frequently (64.7%) in women with thrombosis than in healthy users (32.2%), P0.001. The importance of the immunologic changes as a risk factor in thrombosis in OC users was evaluated in comparison with other predisposing factors and tobacco smoking.


Subject(s)
Antigen-Antibody Complex/analysis , Contraceptives, Oral/adverse effects , Estrogens/immunology , Progesterone Congeners/immunology , Thrombosis/etiology , Adolescent , Adult , Aging , Contraceptives, Oral, Combined/adverse effects , Dose-Response Relationship, Immunologic , Estradiol Congeners/adverse effects , Estradiol Congeners/immunology , Estrogens/adverse effects , Female , Humans , Middle Aged , Progesterone Congeners/adverse effects , Risk , Smoking , Thrombosis/immunology
14.
Pathol Biol (Paris) ; 28(6): 407-12, 1980 Jun.
Article in English | MEDLINE | ID: mdl-6994054

ABSTRACT

The present report describes a simple method of differential flocculation for the various lipoproteins. The method, derived from Seidel, allows estimation of serum HDL (high density lipoproteins) as well as determination of the HDL divided by LDL + VLDL ratio. Using Technicon apparatus, total serum lipoprotein flocculation was measured with a dextran solution, and flocculation of LDL + VLDL (low and very low density lipoproteins) was determined with a heparinate solution. The difference between these two measurements reflected the serum HDL level. Results for several verification tests confirmed the method's reliability and showed it to correlate satisfactorily with other quantity determination techniques.


Subject(s)
Arteriosclerosis/blood , Lipoproteins, HDL/blood , Flocculation , Humans , Lipoproteins, LDL/blood , Lipoproteins, VLDL/blood , Methods
15.
Lipids ; 15(4): 216-23, 1980 Apr.
Article in English | MEDLINE | ID: mdl-7374373

ABSTRACT

The effects of 3 dietary fats (olive oil, canbra oil and butter) on the fatty acids of blood lipids and on serum lipoproteins were compared in 6 healthy adult outpatients, after a 6-day normocaloric diet including 35% of the studied fat. Important, although incomplete, changes appeared in the fatty acid composition of the various serum lipids and in the composition and distribution of serum lipoproteins. These changes probably result from the degree of saturation of the fat ingested. Moreover, differences were observed among individual subjects. Genetic differences, which are important in clinical practice, are stressed in connection with risks of vascular diseases and hyperlipidemia and affect intestinal fat absorption and lipoprotein metabolism.


Subject(s)
Dietary Fats/pharmacology , Lipids/blood , Lipoproteins/blood , Adult , Fasting , Fatty Acids/blood , Female , Food , Humans , Male
17.
Sem Hop ; 55(3-4): 193-7, 1979.
Article in French | MEDLINE | ID: mdl-219528

ABSTRACT

During the last five years, we observed under the microscope all the hyperlipidemic sera received in our laboratory, to search a lipid particle agglutination. We have retained 24 sera with obvious agglutination (9 types V, 9 types IV and 6 types IIb), the lipidemia of which was compared, type to type, to 56 control sera (16 types V, 16 types IV and 24 types IIb), in which no agglutination has been found. We observed significant differences in the means of cholesterol (CT) triglycerides (TG), vitamin A (VA) and CT/TG, VA/TG and VA/CT ratios, comparing agglutinated and control sera. These differences suggest that the agglutination phenomenon is in relation with the nature of the lipid particles present in the hyperlipidemic sera, which could be "chylomicron remnants" in type V hyperlipidemias, and other forms of "remnants" in type IV and IIb hyperlipidemias. These "remnants" could result from a blockade of lipolysis. This blockade of lipolysis in the agglutinated sera might be related to what is known about the authentificated autoimmune hyperlipidemia (AIH). Thus we can suppose that hyperlipidemias with obvious serum lipid particle agglutination are autoimmune hyperlipidemias.


Subject(s)
Autoimmune Diseases , Chylomicrons/blood , Hyperlipidemias/immunology , Agglutination Tests , Cholesterol/blood , Humans , Triglycerides/blood , Vitamin A/blood
18.
Pathol Biol (Paris) ; 26(7): 429-33, 1978 Oct.
Article in French | MEDLINE | ID: mdl-372898

ABSTRACT

During the five last years, we observed under the microscope all the hyperlipidemic sera received in our laboratory, to search a lipid particle agglutination. We have retained 24 sera with obvious agglutination (9 types V, 9 types IV and 6 types IIb), the lipidemia of which was compared, type to type, to 56 control sera (16 types V, 16 types IV and 24 types IIb), in which no agglutination has been found. We observed significant differences in the means of cholesterol (CT) triglycerids (TG), vitamin A (VA) and CT/TG, VA/TG and VA/CT ratios, comparing agglutinated and control sera. These differences suggest that the agglutination phenomenon is in relation with the nature of the lipid particles present in the hyperlipidemic sera, which could be "chylomicron remnants" in type V hyperlipidemias, and other forms of "remnants" in type IV and IIb hyperlipidemias. These "remnants" could result from a blockade of lipolysis. This blockade of lipolysis in the agglutinated sera might be related to what is known about the authentificated autoimmune hyperlipidemia (AIH). Thus we can suppose that hyperlipidemias with obvious serum lipid particle agglutination are autoimmune hyperlipidemias.


Subject(s)
Hyperlipidemias/blood , Lipids/blood , Agglutination , Autoimmune Diseases , Cholesterol/blood , Hyperlipidemias/immunology , Triglycerides/blood
20.
Pathol Biol (Paris) ; 25(5): 333-40, 1977 May.
Article in French | MEDLINE | ID: mdl-69291

ABSTRACT

Site Pg is an antigenic determinant which is present on the surface of serum lipoproteins and reacts with an antilpoprotein myelomatous immunoglobulin, the IgA, Ger. Firstly site Pg is extracted from LDL with the major part of lipids, by an ether-methanol mixture at 6 p. 100. Then the organic substrate obtained is evaporated under vacuum and dissolved in saline before being submitted to an extraction by ehter only. Under these conditions, site Pg remains in the aqueous phase. A polyacrylamide gel filtration on Biogel P2 allows then to separate the substance which reacts with IgA Ger. anti-Pg, from the aqueous phase. The identification of site Pg allowed us to recognize the presence of galactose, phosphorus and choline, and to evaluate its molecular weight of about 330. The reactivity of site Pg with IgA anti-Pg was measured by inhibition of passive hemagglutination and fluorescence quenching. The association constant of site Pg with the whole IgA Ger. or with its Fab fragment could thus be calculated (1.6 10(5) M-1 with the whole IgA; 2.3 10(5) M-1 with the Fab fragment). We showed also that if phosphorylcholine plays an immunodominant role, the presence of sugar seems necessary, since the association constant of the whole IgA Ger. with site Pg is higher than that of IgA Ger. with phosphorylcholine alone.


Subject(s)
Binding Sites, Antibody , Epitopes , Lipoproteins/blood , Chromatography, Gel , Fluorescence , Hemagglutination Tests , Humans , Lipoproteins/immunology , Myeloma Proteins/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...